Sign inSubscribe

target directory

e0302 mecobalamin clinical trial intelligence

Trials are included when the normalized target field matches this target directory. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

1

Directory type

target

Association rule

normalized field

NCT00445172
Source recordAI-normalized

A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS)

The purpose of this study is to investigate the safety and efficacy of long-term E0302 administration in patients with Amyotrophic Lateral Sclerosis (ALS).

AI analysis

Indication: Amyotrophic Lateral Sclerosis (ALS)

Modality: small molecule

Target: E0302 (mecobalamin)

Sponsor: Eisai Co., Ltd.

Source URL: ClinicalTrials.gov

Source updated: Jun 18, 2023

Ingested: Jun 18, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: E0302 (mecobalamin)

View original source fields

Condition raw: Amyotrophic Lateral Sclerosis (ALS)

Condition normalized: Amyotrophic Lateral Sclerosis (ALS)

Modality raw: small molecule

Modality normalized: small molecule

Target raw: E0302 (mecobalamin)

Target normalized: E0302 (mecobalamin)

Open report